NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT04209855,"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression",https://clinicaltrials.gov/study/NCT04209855,MIRASOL,COMPLETED,"This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine (MIRV) vs. IC chemotherapy in participants with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FRα. Participants will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. The FRα positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.",YES,Epithelial Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer,DRUG: Mirvetuximab Soravtansine|DRUG: Paclitaxel|DRUG: Topotecan|DRUG: Pegylated liposomal doxorubicin,"Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, PFS was defined as the time from randomization until progressive disease (PD) or death whichever occurred first. PD: At least a 20% increase in the sum of the longest diameters (SoD) of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 millimeters (mm). Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase., From randomization until PD or death, whichever occurred first (up to 28 months)","Number of Participants With Treatment-emergent Adverse Events (TEAEs), An adverse event (AE) is defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. TEAEs are defined as AEs with an onset date on or after the first dose of Study drug, and within 30 days of the last dose of study drug or prior to the start of a new anticancer treatment, whichever occurrs first., Up to 28 months|Objective Response Rate (ORR), as Assessed by the Investigator Using RECIST v1.1, ORR is defined as percentage of participants with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least 30% decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD., Up to 28 months|Overall Survival Assessed by the Investigator Using RECIST v1.1, Overall survival is defined as the time from the date of first dose until the date of death from any cause, estimated using the Kaplan-Meier method., Up to 30 months|Number of Participants Achieving at Least 15 Point Absolute Improvement at Week 8 or 9 in the Abdominal/GI Scale of European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module 28 (QLQ-OV28), EORTC-QLQ-OV28 includes 3 functional scales (body image, sexuality, attitude to disease/treatment) and 5 symptom scales/items (abdominal/gastrointestinal \[GI\] symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side-effects, and hair loss). Functional scales score (body Image and attitude to disease/treatment) is calculated by averaging scores of all scale items and transforming average scores linearly (1 minus \[average score minus 1\] divided by 3\*100). Functional scales score (sexuality) is calculated by averaging scores of all scale items and transforming average scores linearly (\[average score minus 1\] divided by 3\*100). All of the functional scales range in score from 0 to 100. Higher score represents a higher (""better"") level of functioning. The number of participants achieving at least 15 point absolute improvement at Week 8 or Week 9 in the abdominal/GI scale of the EORTC QLQ-OV28., Baseline and Week 8 or 9|Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1, DOR is defined as the time from the date of the first response (CR or PR), until the date of PD or death from any cause, whichever occurrs first. DOR for participants who has not progressed or died at the time of analysis are censored at the date of their last tumor assessment. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR is estimated using the Kaplan-Meier method., Up to 28 months|Percentage of Participants With CA-125 Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria, The GCIG CA-125 response is defined as at least 50% reduction in CA-125 levels from baseline. The response must have been confirmed and maintained for at least 28 days., Up to 28 months|Time to Second Progression-Free Survival (PFS 2), PFS 2 is defined as the time from date of randomization until second disease progression or death whichever occurs first., Up to 28 months",,AbbVie,Gynecologic Oncology Group|European Network of Gynaecological Oncological Trial Groups (ENGOT),FEMALE,"ADULT, OLDER_ADULT",PHASE3,453,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,IMGN853-0416|2019-003509-80,2019-12-31,2023-03-06,2024-08-22,2019-12-24,2024-08-01,2025-03-25,"University of Alabama at Birmingham (UAB) GYN Oncology, Birmingham, Alabama, 35233, United States|Alaska Women's Cancer Care, Anchorage, Alaska, 99508, United States|Arizona Oncology Associates, PC - HAL - USOR, Phoenix, Arizona, 85016, United States|Mayo Clinic, Phoenix, Arizona, 85054, United States|USOR: Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, 85711, United States|University of Arizona Cancer Center, Tucson, Arizona, 85719, United States|UCLA - JCCC Dept of OBGYN - Women's Health Clinical Research Unit, Los Angeles, California, 90095, United States|Hoag Cancer Center, Newport Beach, California, 92663, United States|University of California San Francisco, San Francisco, California, 94143, United States|Olive View - UCLA Medical Center, Sylmar, California, 91324, United States|Kaiser Permanente Oncology Clinical Trials, Vallejo, California, 94589, United States|USOR: Rocky Mountain Cancer Centers, Lakewood, Colorado, 80228, United States|Yale University School of Medicine, New Haven, Connecticut, 06520, United States|Florida Cancer Specialist South Division, Fort Myers, Florida, 33901, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, 32224, United States|Women's Care Florida / Women's Cancer Associates, Saint Petersburg, Florida, 33701, United States|Florida Cancer Specialist North Division, Saint Petersburg, Florida, 33705, United States|Sarasota Memorial Hospital, Sarasota, Florida, 34239, United States|Florida Cancer Specialists, Tallahassee, Florida, 32308, United States|Florida Cancer Specialist East Division, West Palm Beach, Florida, 33401, United States|Memorial University Medical Center, Savannah, Georgia, 31404, United States|Hawaii Pacific Health - Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, 96813, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, 60005, United States|University of Chicago, Chicago, Illinois, 60637, United States|Dr. Sudarshan K. Sharma, Ltd., Hinsdale, Illinois, 60521, United States|Community Health Network, Indianapolis, Indiana, 46250, United States|University of Kansas Cancer Center, Westwood, Kansas, 66205, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, 41017, United States|Norton Cancer Institute, Louisville, Kentucky, 40207, United States|Ochnser Medical Center Jefferson, New Orleans, Louisiana, 70121, United States|WK Physicians Network/Gynecologic Oncology Associates, Shreveport, Louisiana, 771103, United States|Holy Cross Hospital, Silver Spring, Maryland, 20902, United States|USOR: Maryland Oncology Hematology, P.A., Silver Spring, Maryland, 20902, United States|Tufts Medical Center, Boston, Massachusetts, 02111, United States|Baystate Medical Center, Springfield, Massachusetts, 01199, United States|University of Massachusetts, Worcester, Massachusetts, 01605, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, 48106, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States|USOR: Minnesota Oncology Hematology, PA, Woodbury, Minnesota, 55125, United States|HCA Midwest Kansas City/ Sarah Cannon, Kansas City, Missouri, 64132, United States|Sletten Cancer Institute, Great Falls, Montana, 59405, United States|Center of Hope, Reno, Nevada, 89511, United States|The Valley Hospital, Inc, Ridgewood, New Jersey, 07450, United States|Holy Name Medical Center, Teaneck, New Jersey, 07666, United States|Columbia University Medical Center, New York, New York, 10032, United States|FirstHealth of the Carolinas Outpatient Cancer Center, Pinehurst, North Carolina, 28374, United States|USOR: OHC - Oncology_Hematology Care Clinical Trials, Inc., Cincinnati, Ohio, 45242, United States|MetroHealth Medical Center, Cleveland, Ohio, 44109, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Columbus NCORP, Columbus, Ohio, 43215, United States|Zangmeister Cancer Center, Columbus, Ohio, 43219, United States|Oncology_Hematology Care Clinical Trials, LLC, Fairfield, Ohio, 45014, United States|The Ohio State University Wexner Medical Center, Hilliard, Ohio, 43026, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma, 74146, United States|USOR: Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, 97401, United States|Legacy Gynecologic Oncology, Portland, Oregon, 97210, United States|USOR: Northwest Cancer Specialists, P.C., Portland, Oregon, 97227, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Magee-Women's Hospital-UPMC, Pittsburgh, Pennsylvania, 15213, United States|West Penn Hospital, Pittsburgh, Pennsylvania, 15224, United States|Women & Infants Hospital of Rhode Island, Providence, Rhode Island, 02905, United States|Tennessee Oncology / Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|USOR: Texas Oncology-South Austin, Austin, Texas, 78745, United States|USOR: Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas, 76104, United States|University of Texas, Memorial Hermann, Houston, Texas, 77030, United States|USOR: Texas Oncology - McAllen South Second, McAllen, Texas, 78503, United States|USOR: Texas Oncology - San Antonio, San Antonio, Texas, 78240, United States|USOR: Texas Oncology, P.A., Sugar Land, Texas, 77479, United States|USOR: Texas Oncology - The Woodlands, Gynecologic Oncology, The Woodlands, Texas, 77380, United States|USOR: Texas Oncology - Tyler, Tyler, Texas, 75702, United States|USOR: Texas Oncology, P.A., Webster, Texas, 77598, United States|University of Virginia Health System, Charlottesville, Virginia, 22908, United States|USOR: Virginia Cancer Specialists, PC, Gainesville, Virginia, 20155, United States|Kadlec Clinic Hematology & Oncology, Kennewick, Washington, 99336, United States|West Virginia University- MBRCC, Morgantown, West Virginia, 26506, United States|Newcastle Private Hospital, New Lambton Heights, New South Wales, 2305, Australia|Prince of Wales Hospital, Randwick, New South Wales, 2031, Australia|Monash Health, Clayton, Victoria, 3168, Australia|Oncology Clinics Victoria (OCV) - Cabrini Malvern Hospital Location, Malvern, Victoria, 3144, Australia|Royal North Shore Hospital, Saint Leonards, 2065, Australia|Burnside War Memorial Hospital - The Brian Fricker Oncology Centre, Toorak Gardens, 5065, Australia|OLV Ziekenhuis, Aalst, 9300, Belgium|AZ Klina, Brasschaat, 2390, Belgium|Universitair Ziekenhuis Antwerpen (UZA) - Borstkliniek, Edegem, 2650, Belgium|AZ St-Lucas, Gent, 9000, Belgium|UZ Leuven, Leuven, 3000, Belgium|Complex Oncology Center, Burgas, 8000, Bulgaria|UMHAT Georgi Stranski, Pleven, 5800, Bulgaria|Acibadem City Clinic Tokuda Hospital, Sofia, 1407, Bulgaria|UMHAT ""Sv. Ivan Rilski"", EAD, Sofia, Sofia, 1431, Bulgaria|Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|The Ottawa Hospital General Campus, Ottawa, Ontario, K1H8L6, Canada|Sunnybrook Health Sciences Center, Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, M5G 2M9, Canada|McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada|Centre Hospitalier de L'Universite de Montreal, Montréal, Quebec, H2X 0A9, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, J1H 5N4, Canada|Anhui Provincial Cancer Hospital, Hefei, Anhui, 230000, China|Fujian Cancer Hospital, Fuzhou, Fujian, 350014, China|Zhongshan Hospital Xiamen University, Xiamen, Fujian, 361004, China|Sun Yat-sen University, Cancer Center, Guangzhou, Guangdong, 510060, China|Wuhan Union Hospital of China, Wuhan, Hubei, 430024, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430061, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China|The First Hospital of Jilin University, Changchun, Jilin, 130031, China|Liaoning Cancer Hospital, Shenyang, Liaoning, 110801, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, 710061, China|Peking University First Hospital, Beijing, 100034, China|Beijing Cancer Hospital, Beijing, 100142, China|Fudan University Shanghai Cancer Center, Shanghai, 200032, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, 300060, China|Fakultní nemocnice Ostrava, Ostrava, 708 52, Czechia|Všeobecná fakultní nemocnice v Praze, Praha 2, 128 51, Czechia|KNTB a.s. Zlín, Zlín, 762 75, Czechia|Institut Claudius Regaud, Toulouse, Cedex 9, 31059, France|Centre Oscar Lambret, Lille, Cedex B.P 307, 59020, France|Institut de cancérologie de l'ouest, site Angers, Angers, Cedex, 49055, France|CHRU Besançon, Besançon Cedex, 25030, France|Institut Bergonie, Bordeaux Cedex, 33076, France|Centre Leon Berard, Lyon Cedex, 69373, France|Institut Paoli Calmettes, Marseille, 13009, France|Cochin Hospital, Paris, 75014, France|Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, 75960 Cedex 20, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, 69310, France|Centre Armoricain de radiothérapie, imagerie médicale et oncologie, CARIO, Plerin, 22190, France|Institut Curie, Saint Cloud, 92210, France|ICO Centre René Gauducheau, St. Herblain CEDEX, 44805, France|Institut de cancérologie de Lorraine, Vandoeuvre les Nancy_ Cedex, 54519, France|Gustave Roussy, Villejuif Cedex, 94805, France|Ulm University Hospital Klinik für Frauenheilkunde und Geburtshilfe, Ulm, Baden-Württemberg, 89075, Germany|UMG Göttingen Frauenklinik, Göttingen, Niedersachsen, 37075, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Saxony, 01307, Germany|Universitätsklinikum Bonn, Bonn, 53127, Germany|Städtisches Klinikum Dessau, Zentrum für Klinische Studien, Dessau, 06847, Germany|Klinikum Dortmund gGmbH / Frauenklinik, Dortmund, 44137, Germany|University Hospital Freiburg, Freiburg, 79106, Germany|UKGM Standort Giessen, Giessen, Germany|Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg, 20357, Germany|Wolfson Medical Center, Holon, 5822012, Israel|Hadassah Ein Kerem Medical center, Jerusalem, POB 12000, Israel|Meir Medical Center, Kfar Saba, 4428164, Israel|Sheba Medical Center, Ramat Gan, 5265601, Israel|Kaplan Medical Center, Rehovot, 76100, Israel|Ziv Medical Center, Safed, 13100, Israel|IOV Istituto Oncologico, Padova, PD, 35128, Italy|Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, 25123, Italy|ASST Lecco- Ospedale A.Manzoni, Lecco, 23900, Italy|IRCCS - Istituto Europeo di Oncologia (The European Institute of Oncology) (IEO), Milan, 20141, Italy|INT Pascale, Naples, 80131, Italy|Centro Operativo Studi Clinici S.C.Oncologia Medica, Perugia, 6132, Italy|Oncologia Azienda Osc-IRCCS Reggio Emilia, Reggio Emilia, 42123, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, 00168, Italy|Azienda Ospedaliera Città Della Salute E Della Scienza Di Torino, Torino, 10126, Italy|Ospedale Mauriziano Umberto I, Torino, 10128, Italy|Istituto Oncologico Candiolo, Torino, Italy|National Cancer Center - Center for Uterine Cancer, Gyeonggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, 13620, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Seoul, 03722, Korea, Republic of|University of Ulsan College of Medicine - Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Amsterdam UMC, Amsterdam, 1105 AZ, Netherlands|Maastricht UMC, Maastricht, 6229 HX, Netherlands|Radboud University Medical Center, Nijmegen, Postbus 9101, 6500 HB, Netherlands|Erasmus Medical Center, Rotterdam, 3015 AA, Netherlands|Medical University of Gdansk, Gdańsk, 80-214, Poland|Samodzielny publiczny szpital kliniczny nr 1, Lublin, 20-081, Poland|Wojewódzki Szpital Specjalistyczny, Oddzial Kliniczny Ginekologii Onkologiczne, Olsztyn, 10-561, Poland|Wielkopolskie Centrum Onkologii, Poznań, 61-866, Poland|Szpital Kliniczny im. Ks. Anny Mazowieckiej, Warszawa, 00-315, Poland|Fundação Champalimaud, Lisbon, 1400-038, Portugal|Hospital da Luz, S.A, Lisbon, 1500-650, Portugal|Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisbon, 1649-028, Portugal|Hospital Beatriz Angelo, Loures, 2674-514, Portugal|BIH of Omsk Region ""Clinical Oncology Dispensary"", Omsk, Omsk Oblast, 644013, Russian Federation|LLC ""VitaMed"", Moscow, 10, Russian Federation|Leningrad regional oncology dispensa, St-Petersburg, 194356, Russian Federation|State Autonomous Healthcare Institution Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan, Ufa, 450054, Russian Federation|Oncology and Radiology Institute Serbia, Belgrade, 11000, Serbia|Clinical Center Kragujevac, Kragujevac, 34000, Serbia|Oncology Institute Vojvodina, Surgical Oncology Clinic, Sremska Kamenica, 21204, Serbia|Hospital Clínico de Santiago, Santiago de Compostela, A Coruña, 15706, Spain|H. U. de Jaén, Jaén, Andalucia, 23007, Spain|Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, 28702, Spain|Institut Català d'Oncologia, Badalona, 8916, Spain|H. San Pedro de Alcántara, Caceres, 10003, Spain|Hospital Provincial de Castellon, Castelló, 12002, Spain|Hospital de San Chinarro-Clara Campal, Madrid, 28050, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain|Parc Taulí, Sabadell, 8208, Spain|Virgen del Rocío, Sevilla, 41013, Spain|Hospital de la Fe, Valencia, 46026, Spain|HCU Lozano Blesa, Zaragoza, 50009, Spain|Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan|Mackay Memorial Hospital - Taipei Branch, Taipei City, 10449, Taiwan|Taipei Veterans General Hospital, Taipei City, 11217, Taiwan|Chernihiv Medical Center of Modern Oncology of Chernihiv Regional Council, Chernihiv, Chernihiv Region, 14029, Ukraine|Grigoriev Institute for Medical Radiology NAMS of Ukraine, Kharkiv, Kharkiv Region, 61024, Ukraine|Communal non-profit enterprise ""Khmelnytskyi Regional Antitumor Center"" of Khmelnytskoyi Regional Council, Khmelnytskyi, Khmelnytskyi Region, 29009, Ukraine|Communal non-profit enterprise ""Cherkasy Regional Oncology Dispensary of Cherkasy oblast council"", Cherkasy, 18009, Ukraine|Prykarpatskyi Clinical Oncology Center of Ivano-Frankivsk Regional Council, Ivano-Frankivsk, 76018, Ukraine|Peterborough City Hospital, Peterborough, Cambridgeshire, PE3 9GZ, United Kingdom|Royal Devon and Exeter Hospital (Wonford), Exeter, Devon, EX2 5DW, United Kingdom|University Hospitals Coventry and Warwickshire, Coventry, CV2 2DX, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|St Bartholomew's Hospital-Barts Health NHS Trust, London, EC1A 7BE, United Kingdom|University College London Hospital, London, NW1 2PG, United Kingdom|The Royal Marsden NHS Foundation Trust, London, SM2 5PT, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/55/NCT04209855/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/55/NCT04209855/SAP_001.pdf"
